A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
Recruiting now · Phase 1
Conditions studied: B-cell Non-Hodgkin Lymphoma
In brief
The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.
Key facts
- Study ID
- NCT07661537
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- People needed
- 90
- Starts
- 2026-07-23
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-08-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Aged ≥ 18 years old;
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, expected survival ≥ 3 months;
- Histologically confirmed B-NHL;
- Participant population: Have received ≥ 1 line of standard anti-tumor treatment, and have not achieved response after the latest treatment or have progressive disease after the treatment;
- Have measurable lesions;
- Have adequate organ function;
- Male participants and female participants of childbearing potential must use adequate and effective contraceptive measures during the study and within 3 months after the last drug administration of SHR-3079. Female participants must not be lactating and must have a negative blood HCG test result within 7 days before the first dose;
- Voluntarily sign the ICF, have good compliance, and be willing to cooperate with follow-up.
You may not qualify if…
- Central nervous system (CNS) infiltration;
- Prior chemotherapy or other anti-lymphoma agents administered within 4 weeks before the first dose of study treatment;
- Major surgery within 4 weeks before signing the ICF, or plan to undergo major surgery during the study period;
- Receipt of CAR-T therapy or autologous stem cell transplant within 12 weeks prior to enrollment;
- Receipt of allogeneic hematopoietic stem cell transplantation;
- Prior solid organ transplantation;
- Positive hepatitis C virus (HCV) antibody with HCV-RNA copy number above the upper limit of normal of the study site; positive hepatitis B surface antigen [HBsAg] and/or positive hepatitis B core antibody (HBcAb) with HBV DNA copy number above the upper limit of normal of the study site;
- Presence of severe disorders involving major organ systems;
- Pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention;
- Pregnant, lactating women, or women planning to become pregnant;
- Have other serious physical or mental illness, laboratory test abnormalities, or other factors that may increase the risk of study participation or interfere with the study results.
Where it is running
- Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.